





Administration of RSV vaccines and monoclonal antibodies by age group or cohort

Age group or cohort	RSV vaccines for adults		RSV monoclonal antibodies for infants and children	
	Abrysvo® 0.5mL (Pfizer) 	Arexvy® 0.5 mL (GSK) 	Beyfortus™ (Nirsevimab) 0.5 mL (Purple) (Sanofi) 	Beyfortus™ (Nirsevimab) 1 mL (Blue) (Sanofi) 
Women from 28 weeks pregnancy	NIP FUNDED	DO NOT USE	DO NOT USE	DO NOT USE
Infants and children <24 months	DO NOT USE	DO NOT USE	STATE & TERRITORY FUNDED	STATE & TERRITORY FUNDED
Aboriginal and Torres Strait Islander people ≥60 years	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	NIP FUNDED	DO NOT USE	DO NOT USE
Adults 60-74 years (can consider vaccination)	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	DO NOT USE	DO NOT USE
Adults ≥75 years	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	NIP FUNDED	DO NOT USE	DO NOT USE
Adults with medical risk conditions that increase risk of severe RSV disease <ul style="list-style-type: none"> • 50-59 years (can consider vaccination) • ≥60 years (recommended vaccination) 	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	DO NOT USE	DO NOT USE

Note: **NIP FUNDED** indicates vaccine is NIP funded. **DO NOT USE** indicates product is **NOT** recommended for that group. **STATE & TERRITORY FUNDED** indicates funded under a state and territory program. **AVAILABLE PRIVATELY** indicates product only available through private prescription and is not funded. For further information including dosage and administration, refer to the Australian Immunisation Handbook chapter – [Respiratory syncytial virus \(RSV\)](#)